tbuckley/cabot-search huggingface dataset:
Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Authors: M.G. Cesca, N.C. Pandolfi, M. Barros, V.H.F. de Jesus, V.S. Silva, M. Camandaroba, T.C. Felismino, N. Rodrigues, R.P. Riechelmann
Journal: Annals of Oncology (2019)
Clare Gerada: Mindfulness is useful but not the only option
Authors: Clare Gerada
Journal: BMJ (2019)

Mindfulness has recently been heavily promoted as a solution to the high levels of burnout and mental distress seen among doctors. It has become something of a one-size-fits-all response to a host of modern problems—designed to fit easily into anyone’s life regardless of their background, beliefs, or values.

The reported benefits are broad. They include stress reduction, reduced rumination, decreased negative affect (as in depression and anxiety), less emotional reactivity or more effective regulation of emotion, and increased focus. It’s an impressive list, when you consider its origins …
Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis
Authors: G. Rosati, F. Galli, M. Cantore, S. Lonardi, M. Banzi, M.G. Zampino, R. Mattioli, N. Pella, M. Ronzoni, M Di Bartolomeo, S. Tamberi, P. Marchetti, S. Bozzarelli, D.C. Corsi, A.M. Bochicchio, F. Artioli, R. Labianca, F. Galli, D. Bilancia, G. Bregni
Journal: Annals of Oncology (2019)
NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Authors: M. Guirado, M. Majem, B. Massuti Sureda, R. de las Penas Bataller, A.L. Ortega Granados, M.D. Isla Casado, M. Domine Gomez, R. Marse Fabregat, M.A. Sala, A. Paredes Lario, M.T. Moran Bueno, S. Vazquez Estevez, J. Coves Sarto, J.L. Gonzalez-Larriba, J.M. Sanchez Torres, D. Vicente, N. Farre Bernado, L. Fernandez-Fornos, F. Varcarcel, M. Provencio
Journal: Annals of Oncology (2019)
Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO
Authors: D. Rossini, S. Lonardi, C. Antoniotti, D. Santini, G. Tomasello, G. Aprile, R. Moretto, A.A. Prete, C. Granetto, F. Urbano, B. Borelli, A. Zaniboni, G. Randon, A. Buonadonna, G. Ritorto, C. Barbara, T.P. Latiano, R. Bordonaro, A. Falcone, C. Cremolini
Journal: Annals of Oncology (2019)
Clinical relevance of small tumor size (pT1a-b) for patients with HER2-positive, node-negative breast cancer
Authors: G. Curigliano, L. Fumagalli, V. Bagnardi, N. Rotmensz, M. Locatelli, R. Ghisini, G. Viale, P. Veronesi, A. Goldhirsch
Journal: Journal of Clinical Oncology (2009)

e22011 Background: Prognosis of patients with node-negative, HER2-positive disease and tumor size ≤ 1 cm is a matter of controversy. We assessed the prognostic role of HER2 overexpression/amplification in a large series of patients with node-negative, pT1a,b breast cancers. Methods: All consecutive patients with pT1a,b pN0 M0 HER2-positive breast cancer who underwent surgery at the European Institute of Oncology (IEO) from 1995 to 2006 were identified. No patient received trastuzumab in the adjuvant setting. A matched cohort comparison was done using as variables hormone receptor status (positive vs. negative), age at surgery and year of surgery. Comparison group included patients with HER2-negative breast cancer matched 1:1 for hormone receptor negative group and 1:2 for hormone receptor positive group. We estimated rates of local recurrence, distant metastases, disease free survival (DFS) and overall survival (OS) in the hormone receptor positive and hormone receptor negative group. Results: We identified 150 patients with pT1a,b pN0 M0 HER2-positive tumors. The median follow-up was 4.6 years (range 1.0–9.0). In the hormone receptor positive group 5-year DFS was 99% [95% CI: 98%-100%] for HER2-negative and 92% [95% CI: 86%-99%] for HER2-positive disease. In the hormone receptor negative group 5-year DFS was 92% [95% CI: 84%-100%] for HER2-negative and 91% [95% CI: 84%-99%] in HER2-positive disease. Overall, for patients with hormone receptors positive and negative disease, the hazard ratio (HR) associated to HER2 overexpression was 2.4 (95% CI: 0.9–6.5, p=0.09). OS in HER2-positive pT1a,b pN0 M0 breast cancer was similar in hormone receptor positive and negative patients (p=0.93). Conclusions: Node-negative, HER2-positive, pT1a,b breast cancer have a low risk of locoregional and distant recurrence within the first 5 years after diagnosis. In patients with hormone receptor positive, pT1a,b N0 M0 tumors, HER2 overexpression seems to be associated with a dire prognosis (HR=5.2, 95% CI: 1.0–25.9) in terms of DFS. No significant financial relationships to disclose.
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Authors: Megan A. Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, Emily Rozsahegyi, Nooreen Rubin, Michael P. Sheets, Joseph L. Kim, Chandrasekhar Miduturu, Neil Bifulco, Natasja Brooijmans, Hongliang Shi, Timothy Guzi, Andy Boral, Christoph Lengauer, Marion Dorsch, Richard D. Kim, Yoon-Koo Kang, Beni B. Wolf, Klaus P. Hoeflich
Journal: Cancer Discovery (2019)

Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide with no clinically confirmed oncogenic driver. Although preclinical studies implicate the FGF19 receptor FGFR4 in hepatocarcinogenesis, the dependence of human cancer on FGFR4 has not been demonstrated. Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in patients with HCC with aberrant FGF19 expression. Mutations were identified in the gatekeeper and hinge-1 residues in the kinase domain of FGFR4 upon disease progression in 2 patients treated with fisogatinib, which were confirmed to mediate resistance in vitro and in vivo. A gatekeeper-agnostic, pan-FGFR inhibitor decreased HCC xenograft growth in the presence of these mutations, demonstrating continued FGF19–FGFR4 pathway dependence. These results validate FGFR4 as an oncogenic driver and warrant further therapeutic targeting of this kinase in the clinic. Significance: Our study is the first to demonstrate on-target FGFR4 kinase domain mutations as a mechanism of acquired clinical resistance to targeted therapy. This further establishes FGF19–FGFR4 pathway activation as an oncogenic driver. These findings support further investigation of fisogatinib in HCC and inform the profile of potential next-generation inhibitors. See related commentary by Subbiah and Pal, p. 1646. This article is highlighted in the In This Issue feature, p. 1631
KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA- or ABI-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who had progression on chemotherapy (CTx)
Authors: E. Yu, L. Xu, J. Kim, E.S. Antonarakis
Journal: Annals of Oncology (2019)
Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Authors: A.V. Mitkova, R. Dodova, M. Koleva, A. Andreeva, M. Tzekova-Chernopolska, S. Giragosyan, V.Y. Petkova, I. Terziev, S. Rangelov, C. Slavov, V. Mitev, R.P. Kaneva
Journal: Annals of Oncology (2019)
Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): Real-life outcomes of fifty-eight patients from a Portuguese cancer center
Authors: R.S. Conde, S.C. Ferreira, S. Esteves, I. Claro, A. Moreira, M.T. Marques, M.B. Goncalves
Journal: Annals of Oncology (2019)
The Effect of Ketamine Administration on Pain Control in Painful Crisis of Sickle Cell Anemia Patients during Childhood: A Retrospective Observational Study
Authors: Yurdanur Kilinc, Hacer Temizturk, Hayri levent Yılmaz, Metin Cil, Goksel Leblebisatan, Hatice Ilgen Sasmaz
Journal: Blood (2018)
MGMT methylation in metastatic pancreatic cancer (mPAC): A single center experience
Authors: M. Niger, F. Morano, S. Manglaviti, F. Nichetti, F. Perrone, E. Tamborini, M. Marcuzzo, A. Raimondi, G. Peverelli, M. Brambilla, F. Pagani, M. Torchio, M. Prisciandaro, M. Antista, F. Pietrantonio, S. Pusceddu, G. Pruneri, F.G.M. De Braud, M. Di Bartolomeo
Journal: Annals of Oncology (2019)
Convergence of human and Old World monkey gut microbiomes demonstrates the importance of human ecology over phylogeny
Authors: Katherine R. Amato, Elizabeth K. Mallott, Daniel McDonald, Nathaniel J. Dominy, Tony Goldberg, Joanna E. Lambert, Larissa Swedell, Jessica L. Metcalf, Andres Gomez, Gillian A. O. Britton, Rebecca M. Stumpf, Steven R. Leigh, Rob Knight
Journal: Genome biology (2019)

Comparative data from non-human primates provide insight into the processes that shaped the evolution of the human gut microbiome and highlight microbiome traits that differentiate humans from other primates. Here, in an effort to improve our understanding of the human microbiome, we compare gut microbiome composition and functional potential in 14 populations of humans from ten nations and 18 species of wild, non-human primates.Contrary to expectations from host phylogenetics, we find that human gut microbiome composition and functional potential are more similar to those of cercopithecines, a subfamily of Old World monkey, particularly baboons, than to those of African apes. Additionally, our data reveal more inter-individual variation in gut microbiome functional potential within the human species than across other primate species, suggesting that the human gut microbiome may exhibit more plasticity in response to environmental variation compared to that of other primates.Given similarities of ancestral human habitats and dietary strategies to those of baboons, these findings suggest that convergent ecologies shaped the gut microbiomes of both humans and cercopithecines, perhaps through environmental exposure to microbes, diet, and/or associated physiological adaptations. Increased inter-individual variation in the human microbiome may be associated with human dietary diversity or the ability of humans to inhabit novel environments. Overall, these findings show that diet, ecology, and physiological adaptations are more important than host-microbe co-diversification in shaping the human microbiome, providing a key foundation for comparative analyses of the role of the microbiome in human biology and health.
Evaluation of Infection Prevention and Control Readiness at Frontline Health Care Facilities in High-Risk Districts Bordering Ebola Virus Disease–Affected Areas in the Democratic Republic of the Congo — Uganda, 2018
Authors: Caitlin Biedron, Meghan Lyman, Matthew J. Stuckey, Jaco Homsy, Mohammed Lamorde, Ulzii-Orshikh Luvsansharav, Kathryn Wilson, Danica Gomes, Winifred Omuut, Solome Okware, Judith Nanyondo Semanda, Reuben Kiggundu, Daniel Bulwadda, Vance Brown, Lisa J. Nelson, Alfred Driwale, Ryan Fagan, Benjamin J. Park, Rachel M. Smith
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Infection prevention and control (IPC) in health care facilities is essential to protecting patients, visitors, and health care personnel from the spread of infectious diseases, including Ebola virus disease (Ebola). Patients with suspected Ebola are typically referred to specialized Ebola treatment units (ETUs), which have strict isolation and IPC protocols, for testing and treatment (1,2). However, in settings where contact tracing is inadequate, Ebola patients might first seek care at general health care facilities, which often have insufficient IPC capacity (3-6). Before 2014-2016, most Ebola outbreaks occurred in rural or nonurban communities, and the role of health care facilities as amplification points, while recognized, was limited (7,8). In contrast to these earlier outbreaks, the 2014-2016 West Africa Ebola outbreak occurred in densely populated urban areas where access to health care facilities was better, but contact tracing was generally inadequate (8). Patients with unrecognized Ebola who sought care at health care facilities with inadequate IPC initiated multiple chains of transmission, which amplified the epidemic to an extent not seen in previous Ebola outbreaks (3-5,7). Implementation of robust IPC practices in general health care facilities was critical to ending health care-associated transmission (8). In August 2018, when an Ebola outbreak was recognized in the Democratic Republic of the Congo (DRC), neighboring countries began preparing for possible introduction of Ebola, with a focus on IPC. Baseline IPC assessments conducted in frontline health care facilities in high-risk districts in Uganda found IPC gaps in screening, isolation, and notification. Based on findings, additional funds were provided for IPC, a training curriculum was developed, and other corrective actions were taken. Ebola preparedness efforts should include activities to ensure that frontline health care facilities have the IPC capacity to rapidly identify suspected Ebola cases and refer such patients for treatment to protect patients, staff members, and visitors.
Assessment of dermal fibrosis
Authors: S. Ud‐Din, P. Foden, K. Stocking, M. Mazhari, S. Al‐Habba, M. Baguneid, D. McGeorge, A. Bayat
Journal: British Journal of Dermatology (2019)

The wound healing process can result in the formation of a scar, which replaces normal tissue after injury. Many scar treatments are available but none can totally erase a scar and many can result in a poor outcome. Therefore, in order to evaluate current treatments, as well as research to develop new methods for treating scars, devices which give numerical values at each stage of wound healing are needed. Assessing skin fibrosis (scarring) remains a challenge. This study therefore aimed to find out if high frequency ultrasound (HFUS) and optical coherence tomography (OCT) devices were able to provide a numerical indicator (score) of skin fibrosis over the course of wound healing. This was achieved by recruiting 62 healthy volunteers in Manchester, United Kingdom and carrying out small skin biopsies to their upper inner arms over eight weeks. They had measurements taken each week by HFUS and OCT and this was supported by laboratory analysis. Both devices were able to provide numerical measurements for skin thickness and this was shown to be similar to laboratory measurements. The device software also gave measurements that linked with the amount of collagen in the skin (which gives skin its structure). This was supported by laboratory analysis of different types of collagen. Both techniques were able to identify different structures within the skin but at different depths and resolutions depending upon which device was used. Skin structures were better seen by OCT due to the resolution, whilst HFUS allowed the researchers to see the deeper skin layers. In conclusion, the choice of device is important as this would depend on the type, size and depth of the wound or scar, and specific factors to be investigated or monitored.
Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched study
Authors: M.V. Dieci, C.A. Giorgi, G. Griguolo, S. Angelini, F. Miglietta, T. Giarratano, C. Falci, G. Faggioni, G. Tasca, E. Mioranza, G. Vernaci, A. Menichetti, M. Mantiero, E. Genovesi, S. Frezzini, S. Michieletto, V. Guarneri, T. Saibene
Journal: Annals of Oncology (2019)
Antenatal HIV screening: results from the National Perinatal Survey, France, 2016
Authors: Thi-Chiên Tran, Josiane Pillonel, Françoise Cazein, Cécile Sommen, Camille Bonnet, Béatrice Blondel, Florence Lot
Journal: Eurosurveillance (2019)

BackgroundUniversal antenatal HIV screening programmes are an effective method of preventing mother-to-child transmission.AimsTo assess the coverage and yield of the French programme on a nationally representative sample of pregnant women, and predictive factors for being unscreened or missing information on the performance/ result of a HIV test.MethodsData came from the medical records of women included in the cross-sectional 2016 French National Perinatal Survey. We calculated odds ratios (OR) to identify factors for being unscreened for HIV and for missing information by multivariable analyses.ResultsOf 13,210 women, 12,782 (96.8%) were screened for HIV and 134 (1.0%) were not; information was missing for 294 (2.2%). HIV infection was newly diagnosed in 19/12,769 (0.15%) women screened. The OR for being unscreened was significantly higher in women in legally registered partnerships (OR: 1.3; 95% CI: 1.1-1.6), with 1-2 years of post-secondary schooling (OR: 1.6; 95% CI: 1.2-2.1), part-time employment (OR: 1.4; 95% CI: 1.1-1.8), inadequate antenatal care (OR: 1.9; 95% CI: 1.5-2.4) and receiving care from > 1 provider (OR: 1.8; 95% CI: 1.1-2.8). The OR of missing information was higher in multiparous women (OR: 1.4; 95% CI: 1.2-1.5) and women cared for by general practitioners (OR: 1.4; 95% CI: 1.1-1.9).ConclusionsThe French antenatal HIV screening programme is effective in detecting HIV among pregnant women. However, a few women are still not screened and awareness of the factors that predict this could contribute to improved screening levels.
Ex vivo cytotoxicity and in vivo anti-tumour activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer
Authors: K. Hasegawa, K. Taniguchi, S. Sato, A. Yoshinaga, M. Tsugane, M. Nishiyama, K. Fujiwara
Journal: Annals of Oncology (2019)
Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumour immunity
Authors: A. Samson, E. West, S. Turnbull, K. Scott, E. Tidswell, J. Kingston, M. Johnpulle, K. Bendjama, N. Stojkowitz, M. Lusky, G. Toogood, C.J. Twelves, C. Ralph, A. Anthoney, A. Melcher, F. Collinson
Journal: Annals of Oncology (2019)
Randomized phase II clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Authors: S. Kageyama, Y. Nagata, T. Ishikawa, T. Abe, M. Murakami, T. Kojima, K. Taniguchi, H. Shimada, S. Hirano, S. Ueda, K. Kanetaka, H. Wada, H. Yamaue, E. Sato, Y. Miyahara, N. Goshima, H. Ikeda, T. Yamada, M. Osako, H. Shiku
Journal: Annals of Oncology (2019)
Zwitterionic polymer/polydopamine coating reduce acute inflammatory tissue responses to neural implants
Authors: Asiyeh Golabchi, Bingchen Wu, Bin Cao, Christopher J. Bettinger, Xinyan Tracy Cui
Journal: Biomaterials (2019)

The inflammatory brain tissue response to implanted neural electrode devices has hindered the longevity of these implants. Zwitterionic polymers have a potent anti-fouling effect that decreases the foreign body response to subcutaneous implants. In this study, we developed a nanoscale anti-fouling coating composed of zwitterionic poly (sulfobetaine methacrylate) (PSB) and polydopamine (PDA) for neural probes. The addition of PDA improved the stability of the coating compared to PSB alone, without compromising the anti-fouling properties of the film. PDA-PSB coating reduced protein adsorption by 89% compared to bare Si samples, while fibroblast adhesion was reduced by 86%. PDA-PSB coated silicon based neural probes were implanted into mouse brain, and the inflammatory tissue responses to the implants were assessed by immunohistochemistry one week after implantation. The PSB-PDA coated implants showed a significantly decreased expression of glial fibrillary acidic protein (GFAP), a marker for reactive astrocytes, within 70 μm from the electrode-tissue interface (p < 0.05). Additionally, the coating reduced the microglia activation as shown in decreased Iba-1 and lectin staining, and improved blood-brain barrier integrity indicated by reduced immunoglobulin (IgG) leakage into the tissue around the probes. These findings demonstrate that anti-fouling zwitterionic coating is effective in suppressing the acute inflammatory brain tissue response to implants, and should be further investigated for its potential to improve chronic performance of neural implants.
PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Authors: K. Lee, J.E. Kim, W. Kim, J.-S. Lee, S.Y. Song, M.H. Lee, H.W. Chung, J.S. Song, K.-J. Cho, J.-H. Ahn
Journal: Annals of Oncology (2019)
In Vitro Combination Studies of ACH-4471 with Eculizumab to Assess a Potential Switch Treatment Approach for Paroxysmal Nocturnal Hemoglobinuria
Authors: Dharaben Patel, Jane A Thanassi, Guangwei Yang, Xuan Yuan, Robert A. Brodsky, Mingjun Huang, Steven D Podos
Journal: Blood (2017)
Bevacizumab before cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin: Analysis of early postoperative complication rate and long term follow-up.
Authors: Clarisse Eveno, Guillaume Passot, Diane Goéré, Philippe Soyer, Etienne Gayat, Olivier Glehen, Dominique Elias, Marc Pocard
Journal: Journal of Clinical Oncology (2013)

3642 Background: Patients with stage IV colorectal cancer and peritoneal carcinomatosis are increasingly treated with curative intent and perioperative systemic chemotherapy combined with targeted therapy.The aim of the study was to analyze the potential impact of bevacizumab on early morbidity and survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis of colorectal origin. Methods: From 2004 to 2010, in three referral centers, 182 patients with colorectal carcinomatosis were treated with complete cytoreduction followed by HIPEC after either preoperative systemic chemotherapy alone or in combination with bevacizumab. Because there was no control on treatment allocation, propensity score methods were used to control this bias. Results: The median time from discontinuation of bevacizumab to HIPEC was 7 weeks (range, 6-10). Major morbidity was greater in the Beva group (34 vs. 19%, p=0.020). Nine patients died postoperatively: 5 (6.2%) in the Beva group (n=80) and 4 (3.9%) in the group treated with chemotherapy alone (n=102) (p=NS). The rate of digestive fistulas was greater in the Beva group, although not significant (18 vs. 10%, p=NS). After matching, the effect of Bevacizumab on major morbidity (including death) was found to be significant (OR = 2.28, 95% CI; 1.05 - 4.95) (p=0.04). No difference in median of overall and disease free survival was found between the two groups (12 and 36 month in Beva group vs. 14.3 and 49 month in the control group, p=NS). Conclusions: Administration of bevacizumab before surgery with complete cytoreduction followed by HIPEC for colorectal carcinomatosis is associated with 2-fold increased morbidity. The oncologic benefit of bevacizumab before HIPEC remains to be evaluated with prospective randomized study.
Evaluation of endocrine therapy and patients preferences in early breast cancer: Results of Elena study
Authors: E. Montagna, E. Pagan, V. Bagnardi, M.A. Colleoni, G. Cancello, E. Munzone, S. Dellapasqua, N. Bianco, G.M. Campennì, M. Iorfida, M. Mazza, A. De Maio, M. Milano, P. Veronesi, C. Sangalli, B. Scateni, G. Pravettoni, K. Mazzocco, V. Galimberti
Journal: Annals of Oncology (2019)
Hospital Volume Association With Abdominal Aortic Aneurysm Repair Mortality
Authors: Salvatore T. Scali, Adam W. Beck, Art Sedrakyan, Jialin Mao, Maarit Venermo, Rumi Faizer, Marc Schermerhorn, Barry Beiles, Zoltán Szeberin, Nikolaj Eldrup, Ian Thomson, Kevin Cassar, Martin Altreuther, Christian-Alexander Behrendt, Sebastian Debus, Jonathan R. Boyle, Amundeep Johal, Martin Bjorck, Jack Cronenwett, Kevin Mani
Journal: Circulation (2019)
ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
Authors: R.J. Motzer, C.-H. Lee, H. Emamekhoo, M. Matrana, I. Percent, J.J. Hsieh, A. Hussain, U.N. Vaishampayan, R. Graham, S. Liu, S. McCune, M. Shaheen, H. Parmar, Y. Shen, S.H. Whiting, N.M. Tannir
Journal: Annals of Oncology (2019)